doi: 10.1126/science.6797068.
Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control
- PMID: 6797068
- DOI: 10.1126/science.6797068
Item in Clipboard
Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control
Science.
.
Abstract
Subcutaneous injection of 50 micrograms of a luteinizing hormone-releasing factor agonist (LRF agonist) for three successive days at the time of menstruation in normal cycling women induces a shortened luteal phase with suboptimal concentrations of circulating estradiol and progesterone. This luteal phase defect follows a reduced concentration of follicle-stimulating hormone during the follicular phase and a resulting inadequate follicular maturation. Since a short luteal phase is associated with an endometrium not conductive to implantation, administration of the LRF agonist at the onset of menstrual cycle may prove to be a practical and novel approach to fertility control.
Similar articles
-
Gonadotropin-releasing hormone antagonists: effects on the ovarian follicle and corpus luteum.Clin Obstet Gynecol. 1993 Sep;36(3):744-52. doi: 10.1097/00003081-199309000-00031. Clin Obstet Gynecol. 1993. PMID: 8403621 Review. No abstract available.
-
Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility.Fertil Steril. 1982 Feb;37(2):209-12. Fertil Steril. 1982. PMID: 7037463
-
Regulatory mechanisms during the menstrual cycle.Eur J Obstet Gynecol Reprod Biol. 1980 Oct;11(2):121-44. doi: 10.1016/0028-2243(80)90018-0. Eur J Obstet Gynecol Reprod Biol. 1980. PMID: 6778719 Review. No abstract available.
-
Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.Am J Obstet Gynecol. 1979 Nov 15;135(6):759-63. doi: 10.1016/0002-9378(79)90388-0. Am J Obstet Gynecol. 1979. PMID: 386801
-
Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor.Science. 1979 Jul 27;205(4404):408-10. doi: 10.1126/science.377491. Science. 1979. PMID: 377491
Cited by
-
Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.Reprod Biol Endocrinol. 2010 Oct 22;8:126. doi: 10.1186/1477-7827-8-126. Reprod Biol Endocrinol. 2010. PMID: 20969784 Free PMC article.
-
Breast cancer prevention through modulation of endogenous hormones.Breast Cancer Res Treat. 1993 Nov;28(2):179-93. doi: 10.1007/BF00666430. Breast Cancer Res Treat. 1993. PMID: 8173070 Review.
-
GnRH and its analogues. Current therapeutic applications and new prospects.Drugs. 1984 Mar;27(3):187-93. doi: 10.2165/00003495-198427030-00001. Drugs. 1984. PMID: 6368183 Review. No abstract available.
-
LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women.J Endocrinol Invest. 1985 Aug;8(4):297-302. doi: 10.1007/BF03348501. J Endocrinol Invest. 1985. PMID: 3934254
-
GnRH agonists and antagonists. Current clinical status.Drugs. 1988 Jan;35(1):63-82. doi: 10.2165/00003495-198835010-00004. Drugs. 1988. PMID: 3278879 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
